【ChiCTR1900027713】Comparison of the safety and efficacy of single-stage ERCP plus Laparoscopic cholecystectomy versus two-stage ERCP followed by Laparoscopic cholecystectomy 6 to 8 weeks later
ChiCTR1900027713
结束
/
/
/
2019-11-24
/
/
因胆石症和胆总管结石引起的阻塞性黄疸
Comparison of the safety and efficacy of single-stage ERCP plus Laparoscopic cholecystectomy versus two-stage ERCP followed by Laparoscopic cholecystectomy 6 to 8 weeks later
Comparison of the safety and efficacy of single-stage ERCP plus Laparoscopic cholecystectomy versus two-stage ERCP followed by Laparoscopic cholecystectomy 6 to 8 weeks later
46040
The present study aimed to assess the feasibility of performing cholecystectomy in the same session or same hospitalization following single-stage ERCP in patients with obstructive jaundice due to cholelithiasis and choledocholithiasis.
随机平行对照
其它
The cases were performed by lot by simple randomization method.
No
No financial support in this study
/
43;39;37
/
2017-10-10
2018-10-10
/
Eligibility criteria included no difficulty in ERCP, bile duct stones and cholelithiasis as demonstrated by an imaging method, no suspected or confirmed malignancy, no history of abdominal surgery and absence of contraindications for laparoscopic cholecystectomy.；
请登录查看Exclusion criteria included age under 16 years, pregnancy, diagnostic ERCP, Perforated gallbladder, suspected or confirmed malignancy and uncompleted ERCP. Patients not meeting the eligibility criteria were excluded. ERCP and LC procedures were performed by the same endoscopic surgeon. The indication for ERCP was thoroughly evaluated for each patient in consultation with a radiologist prior to the procedure.；
请登录查看No financial support in this study
46040
No financial support in this study的其他临床试验
土耳其伊玛目大学的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04